Telehealth giant Ro has introduced a new questionnaire aimed at quantifying what is termed “food noise,” a persistent concern among individuals battling obesity. This development underscores the growing influence of telehealth companies in not only treating obesity but also in redefining its clinical understanding. The scale, developed with academic backing, seeks to evaluate how effectively treatments can mitigate patients’ intrusive thoughts about food, a topic gaining traction alongside the rise of GLP-1 medications like Wegovy and Zepbound.
By implementing this scale to monitor patient progress during treatment, Ro is positioning itself at the forefront of obesity management. Furthermore, the licensing of this tool to pharmaceutical companies for use in clinical trials illustrates a strategic move to integrate patient-reported outcomes into drug development, potentially enhancing the efficacy of future obesity therapies and aligning with regulatory expectations for comprehensive treatment assessments.
Open the full market picture for your next decision →
